Profile data is unavailable for this security.
About the company
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. The Company’s clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that is designed with its proprietary single domain antibody, or sdAb, platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist, being investigated as a single agent and in combination with Keytruda, a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors. INBRX-106 is a precisely engineered hexavalent sdAb-based therapeutic candidate targeting OX40, designed to be an optimized agonist of this co-stimulatory receptor.
- Revenue in USD (TTM)1.78m
- Net income in USD-271.16m
- Incorporated2024
- Employees166.00
- LocationInhibrx Biosciences Inc11025 N. Torrey Pines Road, Suite 140LA JOLLA 92037United StatesUSA
- Phone+1 (858) 795-4220
- Fax+1 (302) 636-5454
- Websitehttps://inhibrx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assertio Holdings Inc | 142.05m | -332.97m | 129.37m | 53.00 | -- | 0.9618 | -- | 0.9107 | -3.95 | -3.95 | 1.66 | 1.41 | 0.4081 | 1.19 | 3.19 | 2,680,208.00 | -95.65 | -21.51 | -130.77 | -32.05 | 76.96 | 88.68 | -234.40 | -62.10 | 1.45 | -- | 0.2231 | -- | -2.67 | -13.38 | -402.80 | -- | -28.25 | -- |
| Mediwound Ltd | 19.85m | -12.75m | 134.70m | 100.00 | -- | 5.94 | -- | 6.79 | -1.38 | -1.38 | 2.15 | 2.44 | 0.303 | 5.64 | 5.07 | 198,510.00 | -19.46 | -24.48 | -25.65 | -32.92 | 16.92 | 43.27 | -64.24 | -38.43 | 1.83 | -- | 0.218 | -- | -29.48 | 40.60 | 65.73 | -- | 64.66 | -- |
| Global Pharmatech Inc. | 3.18m | -2.24m | 138.32m | 217.00 | -- | 1.02 | -- | 43.51 | -0.0964 | -0.0964 | 0.1367 | 0.3428 | 0.2292 | 1.59 | 3.57 | 14,649.77 | -16.44 | -- | -22.55 | -- | 46.21 | -- | -71.75 | -- | 1.62 | -9.87 | 0.2223 | -- | 32.43 | -- | -142.03 | -- | -- | -- |
| Lifecore Biomedical Inc | 103.27m | -64.24m | 150.60m | 459.00 | -- | -- | -- | 1.46 | -2.12 | -3.29 | 3.43 | 1.16 | 0.391 | 1.96 | 3.07 | 224,986.90 | -24.32 | -5.67 | -41.13 | -8.07 | 27.10 | 21.91 | -62.20 | -11.90 | 1.35 | -1.05 | 0.7495 | -- | -7.19 | -27.74 | -315.07 | -- | -8.55 | -- |
| OptiNose Inc | 74.02m | -30.75m | 152.08m | 132.00 | -- | -- | -- | 2.05 | -0.2733 | -0.2733 | 0.659 | -0.8777 | 0.7453 | 0.8764 | 4.74 | 560,772.80 | -30.91 | -48.25 | -- | -98.95 | 88.98 | 86.96 | -41.47 | -131.66 | 2.17 | -1.16 | 4.16 | -- | -6.93 | 58.64 | 52.58 | -- | -27.96 | -- |
| Scpharmaceuticals Inc | 17.63m | -57.71m | 153.23m | 135.00 | -- | 6.24 | -- | 8.69 | -1.49 | -1.49 | 0.4545 | 0.6814 | 0.1713 | 0.7566 | 4.02 | 130,607.40 | -56.07 | -38.23 | -62.13 | -42.31 | 71.69 | -- | -327.29 | -1,360.16 | 5.44 | -16.60 | 0.6159 | -- | -- | -- | -48.79 | -- | -- | -- |
| Biostem Technologies Inc | 58.01m | 159.39k | 154.04m | 67.00 | -- | 23.38 | 401.17 | 2.66 | -0.0865 | -0.0865 | 3.60 | 0.4064 | 2.38 | 5.17 | 2.78 | -- | 0.6536 | -- | 9.45 | -- | 94.16 | -- | 0.2748 | -- | 1.10 | 1.23 | 0.3959 | -- | -- | -- | -- | -- | -- | -- |
| ASP Isotopes Inc | 1.27m | -19.62m | 165.64m | 76.00 | -- | 14.79 | -- | 130.08 | -0.5335 | -0.5335 | 0.0344 | 0.2164 | 0.0425 | -- | -- | 16,755.00 | -65.49 | -- | -81.59 | -- | 32.81 | -- | -1,542.66 | -- | -- | -17.39 | 0.633 | -- | -- | -- | -229.34 | -- | -- | -- |
| Zevra Therapeutics Inc | 28.01m | -50.90m | 180.18m | 65.00 | -- | 3.69 | -- | 6.43 | -1.34 | -1.34 | 0.7513 | 1.17 | 0.2172 | -- | 3.47 | 430,876.90 | -39.48 | -32.11 | -47.94 | -39.89 | 51.11 | -- | -181.75 | -128.42 | -- | -- | 0.4683 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
| Elite Pharmaceuticals Inc | 47.32m | 15.55m | 187.78m | 53.00 | 12.09 | 4.05 | 11.11 | 3.97 | 0.0153 | 0.0153 | 0.0465 | 0.0456 | 0.7428 | 2.24 | 4.39 | 892,785.50 | 24.41 | 3.53 | 30.62 | 4.61 | 45.82 | 46.10 | 32.87 | 4.41 | 1.19 | 1.18 | 0.1449 | 0.00 | 5.87 | 35.57 | -59.97 | -- | 83.62 | -- |
| Inhibrx Biosciences Inc | 1.78m | -271.16m | 194.56m | 166.00 | -- | 57.20 | -- | 109.12 | -5.35 | -5.35 | 0.0358 | 0.235 | 0.0066 | -- | 7.51 | 10,740.96 | -99.40 | -77.06 | -123.13 | -93.91 | -- | -- | -15,116.15 | -1,590.91 | -- | -12.67 | 0.9474 | -- | -17.88 | -26.85 | -66.20 | -- | 26.30 | -- |
| Greenwich Lifesciences Inc | 0.00 | -9.24m | 215.10m | 3.00 | -- | 41.99 | -- | -- | -0.719 | -0.719 | 0.00 | 0.3977 | 0.00 | -- | -- | 0.00 | -106.03 | -36.43 | -109.97 | -38.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.63 | -- | -- | -- |
| Aquestive Therapeutics Inc | 51.50m | -28.77m | 219.40m | 135.00 | -- | -- | -- | 4.26 | -0.4273 | -0.4273 | 0.7836 | -0.4012 | 0.5398 | 2.78 | 6.49 | 381,496.30 | -30.15 | -76.63 | -43.46 | -123.85 | 60.23 | 64.24 | -55.85 | -102.95 | 5.85 | -3.51 | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
| CorMedix Inc | 0.00 | -50.24m | 226.98m | 82.00 | -- | 3.91 | -- | -- | -0.9291 | -0.9291 | 0.00 | 1.06 | 0.00 | -- | -- | 0.00 | -78.96 | -54.84 | -88.88 | -62.32 | -- | 6.18 | -- | -18,323.42 | 6.41 | -- | 0.00 | -- | -100.00 | -- | -56.02 | -- | 46.27 | -- |
| Sanara Medtech Inc | 68.00m | -4.89m | 238.23m | 107.00 | -- | 5.50 | -- | 3.50 | -0.5873 | -0.5873 | 8.15 | 5.02 | 1.04 | 1.99 | 8.63 | 635,556.60 | -7.68 | -17.73 | -9.30 | -22.07 | 88.80 | 88.08 | -7.39 | -17.13 | 1.02 | -9.21 | 0.184 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
| Nektar Therapeutics | 90.17m | -175.84m | 238.71m | 137.00 | -- | 1.88 | -- | 2.65 | -0.9195 | -0.9195 | 0.4709 | 0.69 | 0.1883 | 1.93 | 27.27 | 658,153.30 | -36.72 | -31.02 | -41.60 | -34.63 | 60.91 | 78.04 | -195.02 | -372.21 | 5.79 | -25.20 | 0.00 | -- | -2.10 | -40.35 | 25.03 | -- | -42.89 | -- |
Data as of Jul 03 2024. Currency figures normalised to Inhibrx Biosciences Inc's reporting currency: US Dollar USD
30.64%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Viking Global Investors LPas of 29 May 2024 | 1.79m | 12.35% |
| Perceptive Advisors LLCas of 28 May 2024 | 1.46m | 10.10% |
| RA Capital Management LPas of 28 May 2024 | 1.18m | 8.18% |
| KLP Kapitalforvaltning ASas of 31 May 2024 | 1.20k | 0.01% |
More ▼
Data from 31 Mar 2024 - 31 May 2024Source: FactSet Research Systems Inc.
